HUMA · Humacyte, Inc.
$0.50
-0.02 (-4.12%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company will not have sufficient liquidity to fund its operations beyond one year from the issuance of these condensed consolidated financial statements if the Company is unable to generate sufficient cash flows from commercial sales on a timely basis and/or obtain additional capital. These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$154.82M
Shares
277.80M
Volume · Oct 5
6.42M
Avg daily vol (3M)
6.46M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.52
Open$0.51
Day$0.50–0.53
52W close$0.50–2.48
Avg vol 30d4.8M
Short int31.8M · 11.4% float · 7.3d
Short vol74%
Last earningsAug 12, 2026
DataDec 2020–Oct 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 20, 2026
Est · unconfirmed
· in 7 wks
filed Aug 12, 2026
call held Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-70.9%
Trailing year
Short interest
11.4%
Latest settlement · 7.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−40%
below
Price vs 50-day avg
−16%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−13%
trailing
6-month return
−22%
trailing
YTD return
−46%
this year
Relative strength
−34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +42 funds added
Insider flow
Accumulating
Net +$30.4K over 90 days · 0% sells
Short interest
Rising
11.45% of float · ▲ +6.7% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
173 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
EPS growth
+79%
Y/Y
Free cash flow
$-105.9M
Balance sheet
$15.1M
net cash
Quant / Vol
risk profile
Volatility
114%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 11, 2025
2026
Net savings due to workforce reductions, operating cost reductio
up to $38M
incurred and will incur
Aggregate charges representing one-time cash expenditure for sev
$700,000
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−40%
Bearish
Price vs 50-day avg
−16%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +42 funds added
Insider flow
Accumulating
Net +$30.4K over 90 days · 0% sells
Short interest
Rising
11.45% of float · ▲ +6.7% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
173 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 1%
Range high $2
vs 200-day avg -40%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HUMA
this stock
Humacyte, Inc.
|
$154.82M | -45.7% | — | — | 11.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HUMA | -6.4% | -12.5% | -22.2% | +0.7% | -45.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -6.2% | -12.0% | -34.3% | -0.2% | -58.6% |